Allogene Therapeutics Inc

Allogene Therapeutics boosts investor confidence with a Nature Communications breakthrough on ALLO‑329 and a $175 million capital raise, positioning its dual‑target CAR‑T platform as a next‑generation cancer therapy.

Allogene Therapeutics’ senior execs sold shares in March 2026 – see Rule 144 filings, stock price trends and the company’s focus on allogeneic CAR‑T therapy for blood cancers and solid tumors.

Allogene Therapeutics, a Nasdaq‑listed biotech, pioneers allogeneic CAR‑T cell treatments for blood cancers and solid tumors, driving breakthrough cancer therapy innovation.

Allogene Therapeutics, a biotechnology company, is developing innovative allogeneic CAR-T therapies to treat blood cancers and solid tumors, with a market capitalization of approximately $279.57 million.

Allogene Therapeutics, a biotechnology company, is pioneering the development of allogeneic CAR-T therapy, a cutting-edge approach to treating cancer that offers new hope to patients, despite facing financial challenges and volatility in the biotech…

Allogene Therapeutics Inc is at a critical juncture as it prepares to release its Q2 2025 earnings report, which will be a key indicator of the company’s financial health and strategic direction.

Allogene Therapeutics, Inc. is a pioneering biotech company developing innovative allogeneic CAR-T therapies to address challenging blood cancers and solid tumors, with a focus on patient care and accessibility.

Allogene Therapeutics, Inc. is a pioneering biotech company dedicated to developing innovative cancer treatments, particularly allogeneic CAR T-cell therapy, offering hope to patients and families affected by cancer.

Allogene Therapeutics will report its first quarter 2025 financial results and provide a business update on May 13, 2025, followed by a live audio webcast and conference call.